Femasys Announces Notice Of Allowance For New U.S. Patent Application Covering Use Of FemBloc For Female Permanent Birth Control
Portfolio Pulse from Happy Mohamed
Femasys Inc. (NASDAQ:FEMY) has received a Notice of Allowance from the US Patent and Trademark Office for its FemBloc permanent birth control product. The patent, when issued, is expected to expire in 2039. The company plans to continue to prosecute additional patent applications to further enhance its existing patent portfolio.
July 27, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The Notice of Allowance for the FemBloc patent strengthens Femasys' intellectual property position and could potentially increase the commercial value of the product.
The Notice of Allowance for the FemBloc patent from the USPTO strengthens Femasys' intellectual property position. This could potentially increase the commercial value of the product, as it provides a level of protection against competitors. This could lead to increased revenues for the company in the future, which could positively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100